3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
31
Carcinoma, Hepatocellular
18
Neoplasms
13
Neoplasm Metastasis
13
Melanoma
13
Esophageal Neoplasms
12
Nasopharyngeal Carcinoma
10
Head and Neck Neoplasms
9
Esophageal Squamous Cell Carcinoma
9
Colorectal Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Breast Neoplasms
8
Triple Negative Breast Neoplasms
7
Stomach Neoplasms
7
Recurrence
7
Pancreatic Neoplasms
7
Rectal Neoplasms
6
Carcinoma, Renal Cell
6
Biliary Tract Neoplasms
6
Lung Neoplasms
5
Small Cell Lung Carcinoma
4
Sarcoma
4
Ovarian Neoplasms
4
Locally Advanced Rectal Cancer
4
Colonic Neoplasms
4
Advanced NSCLC
4
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Liver Neoplasms
3
Leukemia, Myeloid, Acute
3
Interventions
atezolizumab
2
Gemcitabine
2
Cell Count
2
valrubicin
1
tretazicar
1
pembrolizumab
1
liposomal doxorubicin
1
fludarabine phosphate
1
fludarabine
1
enadenotucirev
1
Vaccines
1
Tumor Necrosis Factor-alpha
1
Radiotherapy
1
Oncolytic Virotherapy
1
Mitomycin
1
Interferons
1
Interferon-beta
1
Immune Checkpoint Inhibitors
1
Genetic Engineering
1
Endostatins
1
Capecitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
1-dodecylpyridoxal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenoviridae Infections
×
Immune Checkpoint Inhibitors
×
Clear all
NCT04673942
2024-10-26
BETA-PRIME
EpicentRx, Inc.
Phase 2
Recruiting
140 enrolled